ProCE Banner Activity

ELARA: Efficacy and Safety of Tisagenlecleucel in Relapsed/Refractory Follicular Lymphoma

Slideset Download
Conference Coverage
Tisagenlecleucel, a CD19 targeted CAR T-cell therapy, demonstrated a high overall response rate with durable responses in adult patients with relapsed/refractory follicular lymphoma.

Released: June 11, 2021

Expiration: June 10, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme